CD532
CAS No. 1639009-81-6
CD532 ( —— )
产品货号. M35289 CAS No. 1639009-81-6
CD532 是一种有效的 Aurora A 激酶抑制剂,IC50 值为 45 nM。CD532 具有阻断 Aurora A 激酶活性和驱动 MYCN 降解的双重作用。CD532 还可以直接与 AURKA 相互作用并诱导整体构象转变。CD532 可用于癌症的研究。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥426 | 有现货 |
|
| 5MG | ¥614 | 有现货 |
|
| 10MG | ¥985 | 有现货 |
|
| 25MG | ¥1869 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称CD532
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述CD532 是一种有效的 Aurora A 激酶抑制剂,IC50 值为 45 nM。CD532 具有阻断 Aurora A 激酶活性和驱动 MYCN 降解的双重作用。CD532 还可以直接与 AURKA 相互作用并诱导整体构象转变。CD532 可用于癌症的研究。
-
产品描述CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer.
-
体外实验CD532 (1-10000 nM; 72 h) is cytotoxic in MYCN-amplified neuroblastoma cell lines SK-N-BE(2) and Kelly, with EC50s of 223.2 nM and 146.7 nM, respectively.CD532 (0.1-1 μM; 24 h) causes dose-dependent loss of MYCN protein in SK-N-BE(2) cells.CD532 (1 μM; 6 h) prevents S-phase entry in SK-N-BE(2) cells.Cell Viability Assay Cell Line:SK-N-BE(2) and Kelly cells Concentration:1, 10, 100, 1000, 10000 nM Incubation Time:72 hours Result :Inhibited the cell viability of SK-N-BE(2) and Kelly cells, with EC50s of 223.2 nM and 146.7 nM, respectively.Cell Cycle Analysis Cell Line:SK-N-BE(2) cells Concentration:1 μM Incubation Time:4 hours Result:Resulted in a rapid and potent loss of S-phase and accumulation in both G0/G1 and G2.Western Blot Analysis Cell Line:SK-N-BE(2) cells Concentration:0.1, 0.25, 0.5, 1 μM Incubation Time:2, 4, 6, 24 hours Result:Causes dose-dependent and time-dependent loss of MYCN protein.
-
体内实验CD532 (25 mg/kg; i.p. twice weekly for 3 weeks) decreases the tumor volume and increases survival in mice with subcutaneous sonic hedgehog (SHH)-subtype medulloblastoma.CD532 (60 mg/kg; i.p. for 2 days) decreases the level of MYCN protein in MYCN-amplified neuroblastoma xenografts.CD532 (20 mg/kg; i.p.) shows a serum half-life of ~1.5 hours and AUC0-24 of 27 μM?h in mice.Animal Model:Homozygous nu/nu mice with SHH-subtype MYCN-expressing medulloblastoma Dosage:25 mg/kg Administration:I.p. twice weekly for 3 weeks Result:Decreased the level of MYCN protein and tumor volume and increases survival.
-
同义词——
-
通路Cell Cycle/DNA Damage
-
靶点Aurora Kinase
-
受体Aurora Kinase
-
研究领域——
-
适应症——
化学信息
-
CAS Number1639009-81-6
-
分子量522.52
-
分子式C26H25F3N8O
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 250 mg/mL (478.45 mM; 超声助溶 )
-
SMILESN(C=1C=C(NN1)C2CCCC2)C3=NC(NC4=CC=C(NC(NC5=CC(C(F)(F)F)=CC=C5)=O)C=C4)=NC=C3
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Gustafson WC, et, al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014 Sep 8;26(3):414-427.?
产品手册
关联产品
-
ENMD-2076
一种多靶点激酶抑制剂,对 Flt3/Aurora A/Src/VEGFR2 的 IC50 为 3/14/23/40 nM;还抑制 Aurora B、c-Kit、FGFR1 (IC50=100-350 nM)。
-
SCH-1473759 hydrochl...
Aurora A 和 B 的有效皮摩尔双重抑制剂,IC50 分别为 0.02 和 0.03 nM;显示出改善的细胞效力(phos-HH3 抑制 IC50=25 nM)和固有水溶性(11.4 mM)。
-
SC-514
SC-514 是一种口服活性、ATP 竞争性 IKK-2 抑制剂,IC50 为 3-12 μM,阻断 NF-κB 依赖性基因表达。
021-51111890
购物车()
sales@molnova.cn

